drugset / Trial / NCT05633810
COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes
RandomizedFactorialQuadruple-blindPrevention
Summary
To evaluate the efficacy and safety of colchicine and non-enteric coated aspirin, combined or alone, to improve cardiovascular outcomes in high-risk patients with type 2 diabetes.
Timeline
- Start
- 2022-12-21
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aspirin | Small molecule | 40 mg | — |
| Comparator | Colchicine | Small molecule | 0.5 mg | — |